Cognitive Decline in Older Patients with End stage Renal Disease

Recruiting

• Conditions: Kidney Failure; cognition; 10038430

• Registration Number: NL-OMON44778
• Lead Sponsor: eids Universitair Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 250

Inclusion Criteria

> 65 years of age with eGFR < 20 ml/min during the past 6 months.

Exclusion Criteria

Illiterat
foreign language
Unable to give informed consent

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Our primary analysis will be to calculate the mean change in MMSE score and<br /><br>cognitive test battery (Stroop, Letter Digit Coding Test and Picture Learning,<br /><br>Immediate and Delayed) after initiation of RRT.<br /><br>To determine whether this change in cognitive function is attributable to the<br /><br>initiation of RRT, we will compare these change to<br /><br>1) change in MMSE score and cognitive and functional test battery in those<br /><br>older patients who did not initiate RRT in two consecutive years (n=200),<br /><br>2) change in MMSE score and cognitive and functional test battery in the<br /><br>individuals who did initiate RRT in two consecutive years prior to start of RRT.<br /><br>3) the association between the change in MMSE score and cognitive and<br /><br>functional test battery after initiation of RRT with various parameters of<br /><br>brain structure (measures of vascular cognitive impairment) or perfusion<br /><br>(measures of auto-regulation) at baseline.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Our secondary analysis will be:<br />1) to evaluate the correlation between the results of CGA and cognitive test<br />battery and cardiovascular markers and disease, metabolic parameters, and (the<br />rate of decline) of eGFR.<br />2) Correlation between outcome of CGA and the impact of disease on quality of<br />life. </p>